Literature DB >> 18616962

Diabetic neuropathy: mechanisms to management.

James L Edwards1, Andrea M Vincent, Hsinlin T Cheng, Eva L Feldman.   

Abstract

Neuropathy is the most common and debilitating complication of diabetes and results in pain, decreased motility, and amputation. Diabetic neuropathy encompasses a variety of forms whose impact ranges from discomfort to death. Hyperglycemia induces oxidative stress in diabetic neurons and results in activation of multiple biochemical pathways. These activated pathways are a major source of damage and are potential therapeutic targets in diabetic neuropathy. Though therapies are available to alleviate the symptoms of diabetic neuropathy, few options are available to eliminate the root causes. The immense physical, psychological, and economic cost of diabetic neuropathy underscore the need for causally targeted therapies. This review covers the pathology, epidemiology, biochemical pathways, and prevention of diabetic neuropathy, as well as discusses current symptomatic and causal therapies and novel approaches to identify therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616962      PMCID: PMC4007052          DOI: 10.1016/j.pharmthera.2008.05.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  405 in total

1.  Lower plasma vitamin C levels in young type I diabetic patients with microalbuminuria.

Authors:  H Dorchy
Journal:  J Diabetes Complications       Date:  1999 Mar-Apr       Impact factor: 2.852

Review 2.  Real-time continuous glucose monitor use and patient selection: what have we learned and where are we going?

Authors:  Darrell M Wilson; Jen Block
Journal:  Diabetes Technol Ther       Date:  2005-10       Impact factor: 6.118

Review 3.  New perspectives on the management of diabetic peripheral neuropathic pain.

Authors:  Troels S Jensen; Misha-Miroslav Backonja; Sergio Hernández Jiménez; Solomon Tesfaye; Paul Valensi; Dan Ziegler
Journal:  Diab Vasc Dis Res       Date:  2006-09       Impact factor: 3.291

4.  NT-3 attenuates functional and structural disorders in sensory nerves of galactose-fed rats.

Authors:  A P Mizisin; M W Kalichman; M Bache; K C Dines; P S DiStefano
Journal:  J Neuropathol Exp Neurol       Date:  1998-09       Impact factor: 3.685

5.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

6.  Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.

Authors:  F J Gómez-Pérez; R Choza; J M Ríos; A Reza; E Huerta; C A Aguilar; J A Rull
Journal:  Arch Med Res       Date:  1996       Impact factor: 2.235

7.  Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study).

Authors:  Tsvetalina Tankova; D Koev; L Dakovska
Journal:  Rom J Intern Med       Date:  2004

8.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.

Authors:  Nozomu Tanji; Glen S Markowitz; Caifeng Fu; Thomas Kislinger; Akihiko Taguchi; Monika Pischetsrieder; David Stern; Ann Marie Schmidt; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2000-09       Impact factor: 10.121

Review 9.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

10.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.

Authors:  T Soulis; M E Cooper; D Vranes; R Bucala; G Jerums
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

View more
  220 in total

1.  Feasibility and effectiveness of a pilot health promotion program for adults with type 2 diabetes: lessons learned.

Authors:  Patricia M Kluding; Rupali Singh; Jeanine Goetz; Jason Rucker; Sarah Bracciano; Natasha Curry
Journal:  Diabetes Educ       Date:  2010-06-08       Impact factor: 2.140

Review 2.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

3.  Taurine reduces nitrosative stress and nitric oxide synthase expression in high glucose-exposed human Schwann cells.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

Review 4.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

Review 5.  Retinal Failure in Diabetes: a Feature of Retinal Sensory Neuropathy.

Authors:  Ellyn J Gray; Thomas W Gardner
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

6.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.

Authors:  Lucy M Hinder; Claudia Figueroa-Romero; Crystal Pacut; Yu Hong; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2013-10-05       Impact factor: 8.401

Review 7.  Neuropathic pain: role for presynaptic T-type channels in nociceptive signaling.

Authors:  Slobodan M Todorovic; Vesna Jevtovic-Todorovic
Journal:  Pflugers Arch       Date:  2013-01-16       Impact factor: 3.657

8.  Neuroprotective and antinociceptive effects of rosemary (Rosmarinus officinalis L.) extract in rats with painful diabetic neuropathy.

Authors:  Bahram Rasoulian; Zahra Hajializadeh; Saeed Esmaeili-Mahani; Marzieh Rashidipour; Iman Fatemi; Ayat Kaeidi
Journal:  J Physiol Sci       Date:  2018-05-12       Impact factor: 2.781

9.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.

Authors:  Lucy M Hinder; Benjamin J Murdock; Meeyoung Park; Diane E Bender; Phillipe D O'Brien; Amy E Rumora; Junguk Hur; Eva L Feldman
Journal:  Exp Neurol       Date:  2018-03-14       Impact factor: 5.330

10.  In-vivo reflectance confocal microscopy of Meissner's corpuscles in diabetic distal symmetric polyneuropathy.

Authors:  Peter D Creigh; Michael P McDermott; Janet E Sowden; Michele Ferguson; David N Herrmann
Journal:  J Neurol Sci       Date:  2017-05-12       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.